Phase 2 Depression and Anxiety Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Generalized Anxiety Disorder according to standard diagnostic guidelines (called DSM-5-TR)
- Women who are not currently pregnant and are not planning to become pregnant during the trial, and men who are not planning to cause a partner to become pregnant during the trial
- People who are willing and able to follow the rules and requirements of the study throughout its duration
Who may not be able to join:
- People who have a significant risk of suicide
- People who have, or have previously had, bipolar disorder, schizophrenia, schizoaffective disorder, a psychotic disorder, or borderline personality disorder, or who have a parent or sibling with a history of psychosis or bipolar disorder
- People who have another mental health condition that is considered their main or primary diagnosis
- People who have other significant health conditions that would make participation in the study unsuitable (confirm with trial site)
- People who have recently used, or who would need to use during the study, medications or therapies that are not permitted by the trial
- People who have a known allergy, sensitivity, or intolerance to the study treatment or to any backup medications that may be used during the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mark Pollack, M.D., Reunion Neuroscience Inc
Phone: 1-888-880-REUN
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
RE104 30 mg versus placebo change from Baseline at Week 4 in Hamilton Anxiety Rating Scale (HAM-A) total score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.